The synthesis and evaluation for iNKT stimulation of α-S-galactosylceramide is reported. Prepared by alkylation of a galactosylthiol, this analog of the potent immunostimulatory agent, KRN7000, did not stimulate iNKT cells either in vitro or in vivo.Invariant Natural Killer T (iNKT) cells are potent regulatory T cells that have been shown to either initiate or shut down a wide range of immune responses. 1 A variety of bacteria, viruses and parasites have been demonstrated to trigger the anti-infective activity of iNKT cells, 2 and iNKT cells have also been implicated in anti-tumor responses. 3 In the absence of microbial or neoplastic triggers, it appears that iNKT cells may regulate the immune system in such a way as to prevent autoimmunity. 4 A little more than a decade ago it was revealed that glycolipids, particularly α-galactosylceramides (α-GalCers), could activate iNKT cells by a pathway involving their binding to a class of antigen presenting protein, CD1d. 5 This discovery has sparked intense efforts to understand the CD1d pathway of iNKT cell activation and to harness it for therapeutic purposes. 6A synthetic α-GalCer, KRN7000 (Figure 1), has been an invaluable tool for dissecting the function of CD1d activated iNKT cells. For example, the use of KRN7000 as a specific agonist for in vivo stimulation has provided evidence suggesting that NKT cell-mediated pathways may be used to inhibit hepatitis B virus replication 7 or protect against cancer, 5 diabetes, 8 malaria 9 and tuberculosis. 10 Not surprisingly, considerable effort has been spent on structure/ activity investigations. These studies have more recently been aided by crystal structures of ligand-bound mouse 11 -and human 12 -CD1d and even more recently by the report of a ternary structure of human iNKT T cell receptor (TCR)/CD1d/KRN7000. 13One key compound to emerge from SAR investigations is α-C-GalCer (Figure 1). 14 Part of the reason it has inspired so much interest is its superiority to KRN7000 in murine model cure ratios for malaria (1000/1 α-C-GalCer/KRN7000) and melanoma (100/1) 15 and for eradication of tumors in mice. 16 The strong activity of α-C-GalCer is not well understood. Both human and mouse CD1d/glycolipid binary structures show a hydrogen bond between CD1d and the anomeric oxygen of the bound α-GalCers (this hydrogen bond is not present in the ternary Correspondence to: Amy R. Howell. Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. iNKT TCR/CD1d/KRN7000 complex). Consequently, it would be anticipated that the stability of the complex of α-C-GalCer, lacking an anomeric oxygen, wit...